Golimumab-Associated Glomerulonephritis

Am J Ther. 2021 Jan-Feb;28(1):e145-e147. doi: 10.1097/MJT.0000000000000946.
No abstract available

MeSH terms

  • Antibodies, Monoclonal / adverse effects
  • Antirheumatic Agents* / therapeutic use
  • Glomerulonephritis* / chemically induced
  • Glomerulonephritis* / drug therapy
  • Humans
  • Injections, Subcutaneous
  • Methotrexate
  • Treatment Outcome
  • Tumor Necrosis Factor-alpha

Substances

  • Antibodies, Monoclonal
  • Antirheumatic Agents
  • Tumor Necrosis Factor-alpha
  • golimumab
  • Methotrexate